Who is sponsoring NCT05982106?

NCT05982106 is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

What condition does NCT05982106 study?

NCT05982106 studies Myelofibrosis.

What drugs are being tested in NCT05982106?

Interventions: TQ05105 Tablets.

What is the status of NCT05982106?

NCT05982106 is currently COMPLETED.

Last reviewed 2023-08-08 · How we verify

To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult Subjects

NCT05982106 PHASE1 COMPLETED

TQ05105 is a class 1 new drug with a new chemical structure developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. It is a Janus Kinase 2 （JAK2）inhibitor and can be used to treat JAK2 target-related diseases. This study is a randomized, open-label, single-center, two-cycle, two-crossover Phase I clinical trial evaluating the effect of food on the pharmacokinetics of TQ05105 tablets in healthy adult subjects. Pharmacokinetic effects and safety after oral administration of TQ05105 tablets.

Details

Lead sponsor	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase	PHASE1
Status	COMPLETED
Enrolment	16
Start date	Mon Jul 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jul 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Myelofibrosis

Interventions

TQ05105 Tablets

Countries

China